LILRA2

Summary

LILRA2 (leukocyte immunoglobulin like receptor A2, HGNC:6603) is a protein-coding gene on chromosome 19q13.42, encoding Leukocyte immunoglobulin-like receptor subfamily A member 2 (Q8N149). Part of the innate immune responses against microbial infection.

This gene encodes a member of a family of immunoreceptors that are expressed predominantly on monocytes and B cells, and at lower levels on dendritic cells and natural killer cells. The encoded protein is an activating receptor that inhibits dendritic cell differentiation and antigen presentation and suppresses innate immune response. Alternatively spliced transcript variants encoding different isoforms have been found. This gene is located in a cluster of related genes on chromosome 19 and there is a pseudogene for this gene on chromosome 3.

Source: NCBI Gene 11027 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 141 total
• MANE Select transcript: NM_001130917

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6603
Approved symbol	LILRA2
Name	leukocyte immunoglobulin like receptor A2
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	LIR-7, ILT1, CD85h, LIR7
Ensembl gene	ENSG00000239998
Ensembl biotype	protein_coding
OMIM	604812
Entrez	11027

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 12 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000251376, ENST00000251377, ENST00000391737, ENST00000391738, ENST00000439534, ENST00000472992, ENST00000495786, ENST00000889282, ENST00000889283, ENST00000889284, ENST00000889285, ENST00000954510, ENST00000954511

RefSeq mRNA: 4 — MANE Select: NM_001130917 NM_001130917, NM_001290270, NM_001290271, NM_006866

CCDS: CCDS12900, CCDS46179, CCDS74453

Canonical transcript exons

ENST00000391738 — 8 exons

Exon	Start	End
ENSE00001373400	54573790	54573912
ENSE00003459519	54574301	54574582
ENSE00003624947	54574076	54574111
ENSE00003888857	54575256	54575552
ENSE00003891467	54587201	54590287
ENSE00003894905	54575807	54576109
ENSE00003895250	54587010	54587060
ENSE00003895381	54574731	54575033

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 98.24.

FANTOM5 (CAGE): breadth broad, TPM avg 7.0833 / max 359.1754, expressed in 371 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177531	5.7953	337
177529	0.7926	183
177530	0.4129	174
177528	0.0825	48

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	98.24	gold quality
granulocyte	CL:0000094	98.17	gold quality
leukocyte	CL:0000738	97.80	gold quality
monocyte	CL:0000576	97.73	gold quality
spleen	UBERON:0002106	93.09	gold quality
bone marrow	UBERON:0002371	92.99	gold quality
bone marrow cell	CL:0002092	90.48	gold quality
vermiform appendix	UBERON:0001154	86.60	gold quality
right lung	UBERON:0002167	81.44	gold quality
upper lobe of left lung	UBERON:0008952	79.13	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	74.57	gold quality
lung	UBERON:0002048	74.45	gold quality
right adrenal gland cortex	UBERON:0035827	73.93	gold quality
smooth muscle tissue	UBERON:0001135	73.27	gold quality
gall bladder	UBERON:0002110	72.72	gold quality
omental fat pad	UBERON:0010414	71.89	gold quality
right adrenal gland	UBERON:0001233	71.66	gold quality
substantia nigra	UBERON:0002038	71.51	gold quality
placenta	UBERON:0001987	71.50	gold quality
adipose tissue	UBERON:0001013	71.05	gold quality
right coronary artery	UBERON:0001625	70.99	gold quality
left adrenal gland	UBERON:0001234	70.95	gold quality
subcutaneous adipose tissue	UBERON:0002190	70.40	gold quality
left adrenal gland cortex	UBERON:0035825	70.37	gold quality
left uterine tube	UBERON:0001303	70.20	gold quality
descending thoracic aorta	UBERON:0002345	69.32	gold quality
left coronary artery	UBERON:0001626	69.13	gold quality
lymph node	UBERON:0000029	68.81	gold quality
adrenal gland	UBERON:0002369	68.29	gold quality
liver	UBERON:0002107	67.82	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-CURD-46	yes	32.52
E-CURD-88	yes	21.13
E-MTAB-6701	yes	13.13
E-HCAD-10	yes	7.76
E-ANND-3	yes	4.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting LILRA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-488-5P	99.28	68.12	821
HSA-MIR-10524-5P	99.05	66.08	963
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-6876-3P	98.97	65.69	765
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-626	98.89	66.21	762
HSA-MIR-198	98.70	67.32	920
HSA-MIR-338-3P	98.14	67.38	1137
HSA-MIR-6802-3P	97.29	65.42	613
HSA-MIR-517-5P	97.13	68.43	781

Literature-anchored findings (GeneRIF, showing 11)

• LIR7 is an activating receptor for eosinophils that elicited the release of cytotoxic granule proteins, de novo lipid mediator generation, and cytokine release through vesicular transport (PMID:12529506)
• Cross-linking of basophil LIR7 resulted in the concentration-dependent net release of histamine and cysteinyl leukotrienes that were maximal at 30 minutes, and of IL-4 that was maximal at 4 hours (PMID:15242876)
• Progenitor mast cells expressed cell surface activating LILRA2. Mature cord-blood-derived mast cells had detectable mRNA encoding multiple LILRs, none were expressed on the cell surface. (PMID:17998301)
• LILRA2 activation, by altering GM-CSF-induced monocyte differentiation into immature DC, provides a mechanism for down-regulating the ability of the innate immune system to activate the adaptive T cell response while promoting an inflammatory response. (PMID:18056355)
• LILRA2 Delta 419-421 isoform encoded by the splice site SNP may play a role in systemic lupus erythematosus and microscopic polyangiitis. (PMID:18273033)
• The authors report the LILRA2 extracellular D1D2 domain crystal structure, which reveals structural shifts of the corresponding MHC-binding amino acid residues in comparison with LILR B1/B2, explaining its non-binding to MHC molecules. (PMID:19230061)
• LILRA2-mediated activation of monocytes is significantly different to LPS and that LILRA2 selectively modulates LPS-mediated monocyte activation and FcgammaRI-dependent phagocytosis. (PMID:22479404)
• LILRA2 recognizes microbially cleaved antibodies and activates innate immunity, suggesting that LILRA2 detects dangerous immunological situations in which antibodies are destroyed by pathogens. (PMID:27572839)
• findings demonstrate that LILRA2 is a type of innate immune receptor in the host immune system that detects immunoglobulin abnormalities caused by microbial pathogens. (PMID:27572839)
• Molecular mechanism of the recognition of bacterially cleaved immunoglobulin by the immune regulatory receptor LILRA2. (PMID:32424043)
• Overexpression of LILRA2 indicated poor prognosis of ovarian carcinoma: A new potential biomarker and therapeutic target. (PMID:36720556)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lilra6	ENSMUSG00000030427
mus_musculus	Pirb	ENSMUSG00000058818
mus_musculus	Lilra5	ENSMUSG00000070873
mus_musculus	Pira12	ENSMUSG00000074417
mus_musculus	Pira13	ENSMUSG00000074419
mus_musculus	Pira1	ENSMUSG00000081665
mus_musculus	Pira2	ENSMUSG00000089942
rattus_norvegicus	Lilra5	ENSRNOG00000027808
rattus_norvegicus	Lilrb3	ENSRNOG00000046683
rattus_norvegicus	Lilrb2	ENSRNOG00000054954
rattus_norvegicus	Lilrc2	ENSRNOG00000058087
rattus_norvegicus	Pirb	ENSRNOG00000058422
rattus_norvegicus	LOC134485274	ENSRNOG00000062907
rattus_norvegicus		ENSRNOG00000067708
rattus_norvegicus		ENSRNOG00000069029

Paralogs (25): GP6 (ENSG00000088053), LILRB1 (ENSG00000104972), LILRA1 (ENSG00000104974), LILRB5 (ENSG00000105609), A1BG (ENSG00000121410), KIR2DL1 (ENSG00000125498), LILRB2 (ENSG00000131042), IGSF1 (ENSG00000147255), LAIR2 (ENSG00000167618), KIR3DL1 (ENSG00000167633), OSCAR (ENSG00000170909), FCAR (ENSG00000186431), LILRB4 (ENSG00000186818), LILRA5 (ENSG00000187116), KIR2DL4 (ENSG00000189013), VSTM1 (ENSG00000189068), NCR1 (ENSG00000189430), LILRB3 (ENSG00000204577), KIR2DS4 (ENSG00000221957), LILRA4 (ENSG00000239961), KIR3DL2 (ENSG00000240403), KIR3DL3 (ENSG00000242019), KIR2DL3 (ENSG00000243772), LILRA6 (ENSG00000244482), TARM1 (ENSG00000248385)

Protein

Protein identifiers

Leukocyte immunoglobulin-like receptor subfamily A member 2 — Q8N149 (reviewed: Q8N149)

Alternative names: CD85 antigen-like family member H, Immunoglobulin-like transcript 1, Leukocyte immunoglobulin-like receptor 7

All UniProt accessions (4): Q8N149, A0A087WT41, A8MZH0, E9PDF4

UniProt curated annotations — full annotation on UniProt →

Function. Part of the innate immune responses against microbial infection. Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans. Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling. Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1. Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils. In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4. In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4. Does not bind class I MHC antigens.

Subunit / interactions. Homodimer.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Detected on the surface of all peripheral blood monocytes, neutrophils, basophils and eosinophils (at protein level). Expression levels are very low or not detectable on monocytes, T-cells, B-cells, dendritic cells and natural killer (NK) cells.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N149-1	1	yes
Q8N149-2	2
Q8N149-3	3
Q8N149-4	4

RefSeq proteins (4): NP_001124389, NP_001277199, NP_001277200, NP_006857 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016332	A1B_glyco/leuk_Ig-like_rcpt	Family
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050412	Ig-like_Receptors_ImmuneReg	Family

Pfam: PF00047, PF13895

UniProt features (44 total): strand 15, glycosylation site 7, sequence variant 5, disulfide bond 4, domain 4, splice variant 3, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2OTP	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N149-F1	86.47	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 404

Disulfide bonds (4): 49–97, 143–195, 244–295, 344–395

Glycosylation sites (7): 64, 103, 138, 279, 300, 339, 429

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 219 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, GOBP_POSITIVE_REGULATION_OF_CALCIUM_ION_TRANSPORT, GOBP_REGULATION_OF_CELL_ACTIVATION, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_8_PRODUCTION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, MODULE_45, MODULE_64, GOBP_REGULATION_OF_TOLL_LIKE_RECEPTOR_4_SIGNALING_PATHWAY, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, MODULE_16, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND

GO Biological Process (19): innate immune response activating cell surface receptor signaling pathway (GO:0002220), neutrophil activation involved in immune response (GO:0002283), immune response-regulating signaling pathway (GO:0002764), defense response (GO:0006952), signal transduction (GO:0007165), negative regulation of lipopolysaccharide-mediated signaling pathway (GO:0031665), positive regulation of granulocyte macrophage colony-stimulating factor production (GO:0032725), positive regulation of interleukin-1 beta production (GO:0032731), positive regulation of interleukin-6 production (GO:0032755), positive regulation of interleukin-8 production (GO:0032757), positive regulation of tumor necrosis factor production (GO:0032760), negative regulation of toll-like receptor 4 signaling pathway (GO:0034144), innate immune response (GO:0045087), positive regulation of cell activation (GO:0050867), positive regulation of calcium ion transport (GO:0051928), positive regulation of granulocyte colony-stimulating factor production (GO:0071657), interleukin-10-mediated signaling pathway (GO:0140105), immune system process (GO:0002376), cell surface receptor signaling pathway (GO:0007166)

GO Molecular Function (4): IgM binding (GO:0001791), antigen binding (GO:0003823), inhibitory MHC class I receptor activity (GO:0032396), signaling receptor activity (GO:0038023)

GO Cellular Component (3): extracellular region (GO:0005576), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Adaptive Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of cytokine production	3
immune response	2
signal transduction	2
negative regulation of signal transduction	2
cellular anatomical structure	2
immune response-activating cell surface receptor signaling pathway	1
innate immune response-activating signaling pathway	1
myeloid cell activation involved in immune response	1
neutrophil activation	1
regulation of immune response	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
negative regulation of response to biotic stimulus	1
lipopolysaccharide-mediated signaling pathway	1
regulation of lipopolysaccharide-mediated signaling pathway	1
negative regulation of response to external stimulus	1
granulocyte macrophage colony-stimulating factor production	1
regulation of granulocyte macrophage colony-stimulating factor production	1
positive regulation of protein metabolic process	1
interleukin-1 beta production	1
regulation of interleukin-1 beta production	1
positive regulation of interleukin-1 production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
interleukin-8 production	1
regulation of interleukin-8 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
negative regulation of immune system process	1
toll-like receptor 4 signaling pathway	1
regulation of toll-like receptor 4 signaling pathway	1
defense response to symbiont	1
cell activation	1
positive regulation of cellular process	1
regulation of cell activation	1

Protein interactions and networks

STRING

1216 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LILRA2	CD300C	Q08708	915
LILRA2	FCER1G	P30273	897
LILRA2	TYROBP	O43914	655
LILRA2	PTPN6	P29350	592
LILRA2	RNASE2	P10153	541
LILRA2	HLA-A	P01891	522
LILRA2	LILRB4	Q8NHJ6	494
LILRA2	IL10	P22301	494
LILRA2	CD1B	P29016	487
LILRA2	CD83	Q01151	486
LILRA2	LAIR1	Q6GTX8	470
LILRA2	CD1C	P29017	447
LILRA2	PLIN1	O60240	440
LILRA2	CORO1A	P31146	435
LILRA2	PLIN2	Q99541	435

IntAct

5 interactions, top by confidence:

A	B	Type	Score
LILRA2	FCGRT	psi-mi:“MI:0915”(physical association)	0.400
MOG	LILRA2	psi-mi:“MI:0915”(physical association)	0.400
ECE1	LILRA2	psi-mi:“MI:0915”(physical association)	0.370

ESM2 similar proteins: A0A0K2S4Q6, A2A7V7, A6NI73, A8K4G0, O43699, O75019, O75022, O75023, O75871, O76036, P0C191, P20138, P24071, P40198, P59901, P80943, Q08708, Q13410, Q28110, Q3U497, Q496F6, Q64JA4, Q6GTX8, Q6ISS4, Q6PI73, Q6UXZ3, Q7TSN2, Q863H2, Q8C567, Q8K249, Q8MJZ2, Q8MJZ7, Q8N149, Q8N423, Q8N6C8, Q8NHJ6, Q8NHL6, Q8VBT3, Q8VCH2, Q95JB9

Diamond homologs: A0A0G2KBC9, A6NI73, C0HJX2, C0HJX3, D3ZQX2, O75019, O75022, O75023, O76036, P0C191, P24071, P43626, P43629, P43630, P59901, P83556, P97484, Q14943, Q14954, Q61450, Q64281, Q6GTX8, Q6ISS4, Q6PI73, Q7TQA1, Q863H2, Q8C567, Q8IYS5, Q8MJZ2, Q8MJZ7, Q8N109, Q8N149, Q8N423, Q8N6C8, Q8N743, Q8NHJ6, Q8NHK3, Q8NHL6, Q95JB9, Q9HCN6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

141 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	110
Likely benign	18
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1200 predictions. Top by Δscore:

Variant	Effect	Δscore
19:54574847:G:GT	donor_gain	1.0000
19:54574729:A:AG	acceptor_gain	0.9900
19:54574730:G:GG	acceptor_gain	0.9900
19:54574730:GGA:G	acceptor_gain	0.9900
19:54574848:A:T	donor_gain	0.9900
19:54575548:CACAG:C	donor_loss	0.9900
19:54575549:ACAG:A	donor_loss	0.9900
19:54575552:GGTGA:G	donor_loss	0.9900
19:54575553:GT:G	donor_loss	0.9900
19:54575554:T:G	donor_loss	0.9900
19:54573909:CTCGG:C	donor_loss	0.9800
19:54573910:TCGGT:T	donor_loss	0.9800
19:54573913:GTG:G	donor_loss	0.9800
19:54573914:T:A	donor_loss	0.9800
19:54574726:CCTA:C	acceptor_loss	0.9800
19:54574728:TA:T	acceptor_loss	0.9800
19:54574729:A:AC	acceptor_loss	0.9800
19:54574902:G:GA	donor_gain	0.9800
19:54575840:AGCC:A	acceptor_gain	0.9800
19:54575841:GCCG:G	acceptor_gain	0.9800
19:54573915:G:GG	donor_loss	0.9700
19:54573978:GTCCC:G	donor_gain	0.9700
19:54573979:TCCCT:T	donor_gain	0.9700
19:54575032:AGGT:A	donor_loss	0.9700
19:54575033:GGTGA:G	donor_loss	0.9700
19:54575034:G:GA	donor_loss	0.9700
19:54575253:CAGG:C	acceptor_loss	0.9700
19:54575254:A:AC	acceptor_loss	0.9700
19:54575255:G:GT	acceptor_loss	0.9700
19:54575806:GGACA:G	acceptor_gain	0.9700

AlphaMissense

3091 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:54575992:T:C	F380L	0.969
19:54575994:C:A	F380L	0.969
19:54575994:C:G	F380L	0.969
19:54575357:T:C	F253L	0.943
19:54575359:T:A	F253L	0.943
19:54575359:T:G	F253L	0.943
19:54574474:T:C	F82L	0.941
19:54574476:C:A	F82L	0.941
19:54574476:C:G	F82L	0.941
19:54575438:T:C	F280L	0.938
19:54575440:C:A	F280L	0.938
19:54575440:C:G	F280L	0.938
19:54575993:T:G	F380C	0.937
19:54575911:T:C	F353L	0.930
19:54575913:C:A	F353L	0.930
19:54575913:C:G	F353L	0.930
19:54574375:T:A	C49S	0.929
19:54574376:G:C	C49S	0.929
19:54575006:A:C	S210R	0.920
19:54575008:T:A	S210R	0.920
19:54575008:T:G	S210R	0.920
19:54576082:A:C	S410R	0.919
19:54576084:T:A	S410R	0.919
19:54576084:T:G	S410R	0.919
19:54575525:A:C	S309R	0.917
19:54575527:T:A	S309R	0.917
19:54575527:T:G	S309R	0.917
19:54574832:T:C	F152L	0.915
19:54574834:C:A	F152L	0.915
19:54574834:C:G	F152L	0.915

dbSNP variants (sampled 300 via entrez): RS1000101165 (19:54577741 G>A,T), RS1000107535 (19:54573840 C>T), RS1000174357 (19:54585879 T>C), RS1000283635 (19:54579648 A>G), RS1000396759 (19:54581957 C>A,T), RS1000594808 (19:54578129 A>G), RS1000648950 (19:54578332 T>C), RS1000709868 (19:54574675 G>A), RS1000766375 (19:54581723 G>A), RS1000929496 (19:54585782 G>A), RS1000960384 (19:54589042 A>T), RS1001225958 (19:54581614 T>C), RS1001278417 (19:54581828 A>G,T), RS1001289634 (19:54581949 A>C,G), RS1001797543 (19:54586843 T>C)

Disease associations

OMIM: gene MIM:604812 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation, affects methylation	2
Tretinoin	increases expression	2
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
tamibarotene	affects expression	1
di-n-butylphosphoric acid	affects expression	1
dihydroxy-vitamin D3	decreases expression	1
(+)-JQ1 compound	decreases expression	1
MT19c compound	decreases expression	1
Pioglitazone	decreases expression	1
Aspirin	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment, decreases expression	1
Mercury	decreases expression	1
Nickel	increases expression	1
Testosterone	increases expression	1
Valproic Acid	increases methylation	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
beta-Naphthoflavone	decreases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.